Edition:
India

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

8.72USD
25 Jun 2019
Change (% chg)

-- (--)
Prev Close
$8.72
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
136,958
52-wk High
$14.96
52-wk Low
$8.07

Latest Key Developments (Source: Significant Developments)

ChemoCentryx Reports Qtrly Loss Per Share $0.23
Tuesday, 7 May 2019 

May 6 (Reuters) - ChemoCentryx Inc ::CHEMOCENTRYX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q1 REVENUE $8.3 MILLION VERSUS $9.5 MILLION.Q1 REVENUE ESTIMATE $11 MILLION -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $234.1 MILLION AT MARCH 31, 2019.COMPANY EXPECTS TO UTILIZE CASH AND INVESTMENTS IN RANGE OF $75.0 MILLION TO $85.0 MILLION IN 2019.QTRLY LOSS PER SHARE $0.23.Q1 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $11.0 MILLION -- REFINITIV IBES DATA.  Full Article

Chemocentryx Posts Qtrly Loss Per Share Of $0.21
Tuesday, 12 Mar 2019 

March 11 (Reuters) - ChemoCentryx Inc ::CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q4 REVENUE $9.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $9.4 MILLION.QTRLY LOSS PER SHARE $0.21.EXPECTS TO UTILIZE CASH AND INVESTMENTS IN RANGE OF $75.0 MILLION AND $85.0 MILLION IN 2019.  Full Article

Chemocentryx Announces Proposed Public Offering Of $75 Mln Of Its Common Stock
Thursday, 27 Sep 2018 

Sept 26 (Reuters) - ChemoCentryx Inc ::CHEMOCENTRYX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CHEMOCENTRYX INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $75 MILLION OF ITS COMMON STOCK.  Full Article

Chemocentryx Q4 Revenue $56.3 Million Versus $4.9 Million
Friday, 9 Mar 2018 

March 9 (Reuters) - Chemocentryx Inc ::CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q4 REVENUE $56.3 MILLION VERSUS $4.9 MILLION.Q4 REVENUE VIEW $9.4 MILLION -- THOMSON REUTERS I/B/E/S.QUARTERLY EARNINGS PER SHARE $0.80.  Full Article

Chemocentryx reports Q3 revenue $9.0 million
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Chemocentryx Inc ::Chemocentryx reports third quarter 2017 financial results and recent highlights.Q3 revenue $9.0 million versus I/B/E/S view $9 million.Chemocentryx Inc - ‍expects to utilize cash and cash equivalents in range of $50 million and $55 million in 2017​.Chemocentryx inc - ‍phase iii advocate trial of avacopan remains on track to complete enrollment in mid-2018​.Chemocentryx Inc - ‍plan to launch registration-supporting trial for CCX140 in treatment of focal segmental glomerulosclerosis (FSGS) in Q4 2017​.Chemocentryx Inc - qtrly loss per share $0.13​.  Full Article